Regulus Therapeutics Inc (RGLS) Sees Large Volume Increase Following Insider Buying Activity

Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) saw unusually-strong trading volume on Friday following insider buying activity. Approximately 4,278,434 shares changed hands during mid-day trading, an increase of 364% from the previous session’s volume of 921,250 shares.The stock last traded at $1.40 and had previously closed at $1.25.

Specifically, Director Stelios Papadopoulos purchased 500,000 shares of the firm’s stock in a transaction on Wednesday, March 22nd. The shares were acquired at an average price of $1.22 per share, for a total transaction of $610,000.00. Following the purchase, the director now directly owns 400,677 shares in the company, valued at $488,825.94. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director William H. Rastetter purchased 250,000 shares of the firm’s stock in a transaction on Tuesday, March 7th. The stock was bought at an average price of $1.15 per share, for a total transaction of $287,500.00. The disclosure for this purchase can be found here. Corporate insiders own 2.30% of the company’s stock.

Several analysts have recently issued reports on the stock. Needham & Company LLC cut shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 30th. Zacks Investment Research cut shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 8th. Cantor Fitzgerald decreased their target price on shares of Regulus Therapeutics from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, March 3rd. Cowen and Company restated a “hold” rating on shares of Regulus Therapeutics in a research report on Friday, March 3rd. Finally, Wedbush reduced their price objective on shares of Regulus Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a research report on Monday, January 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. Regulus Therapeutics has an average rating of “Hold” and an average price target of $5.68.

The company has a 50-day moving average price of $1.40 and a 200 day moving average price of $2.09. The company’s market cap is $74.10 million.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, March 2nd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.01. Regulus Therapeutics had a negative return on equity of 70.38% and a negative net margin of 573.63%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.20 million. Analysts anticipate that Regulus Therapeutics Inc will post ($1.34) earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Tudor Investment Corp Et Al bought a new stake in Regulus Therapeutics during the fourth quarter worth $105,000. Teachers Advisors LLC increased its stake in Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 9,804 shares during the last quarter. A.R.T. Advisors LLC increased its stake in Regulus Therapeutics by 405.0% in the fourth quarter. A.R.T. Advisors LLC now owns 90,400 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 72,500 shares during the last quarter. Piermont Capital Management Inc. increased its stake in Regulus Therapeutics by 9.3% in the third quarter. Piermont Capital Management Inc. now owns 166,104 shares of the biopharmaceutical company’s stock worth $548,000 after buying an additional 14,180 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in Regulus Therapeutics by 23.4% in the third quarter. Wells Fargo & Company MN now owns 630,332 shares of the biopharmaceutical company’s stock worth $2,081,000 after buying an additional 119,668 shares during the last quarter. 50.10% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2017/04/21/regulus-therapeutics-inc-rgls-sees-strong-trading-volume-on-insider-buying-activity-updated-updated.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

5 Day Chart for NASDAQ:RGLS

Receive News & Ratings for Regulus Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply